{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:48:00Z","timestamp":1792126080479,"version":"4.4.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jdcr.2026.08.038","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:45:15Z","timestamp":1787931915000},"page":"175-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Topical ruxolitinib for prebullous phase of immune checkpoint Inhibitor\u2013Induced bullous pemphigoid"],"prefix":"10.1016","volume":"76","author":[{"given":"Ines","family":"Lederbogen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-5066","authenticated-orcid":false,"given":"Barbara","family":"Meier-Schiesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jdcr.2026.08.038_bib1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.anai.2021.02.009","article-title":"Immune-related cutaneous adverse events due to checkpoint inhibitors","volume":"126","author":"Wang","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.jdcr.2026.08.038_bib2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/14740338.2019.1619693","article-title":"Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system","volume":"18","author":"Aggarwal","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"10.1016\/j.jdcr.2026.08.038_bib3","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jaad.2025.01.086","article-title":"Bullous pemphigoid: a practical approach to diagnosis and management in the modern era","volume":"92","author":"Powers","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2026.08.038_bib4","article-title":"JAK-STAT pathway, type I\/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid","volume":"16","author":"Lin","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jdcr.2026.08.038_bib5","article-title":"Janus kinase inhibitors in autoimmune bullous diseases","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626005321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626005321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:27:15Z","timestamp":1792124835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626005321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":5,"alternative-id":["S2352512626005321"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.08.038","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical ruxolitinib for prebullous phase of immune checkpoint Inhibitor\u2013Induced bullous pemphigoid","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.08.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}